Related Experiment Video
Updated: Jul 14, 2026
08:02
In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
Published on: September 23, 2021
Engineered Extracellular Vesicles as Programmable Immune Interfaces: Surface and Cargo Engineering for Cancer
Tomoyoshi Yamano1,2, Rikinari Hanayama1,2
1Department of Immunology, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8640, Japan.
Cells
|July 13, 2026
Summary
Engineered extracellular vesicles (EVs) act as programmable immune interfaces for targeted therapies. These nanoscale platforms offer versatile strategies for cancer immunotherapy and immune regulation, advancing next-generation therapeutics.
Area of Science:
- Immunology
- Nanotechnology
- Biotechnology
Background:
- Extracellular vesicles (EVs) are key mediators of intercellular communication via transferred biomolecules.
- Their inherent properties like biocompatibility and targeted delivery make them promising therapeutic platforms.
- Engineering EVs transforms them into programmable interfaces for modulating immune responses.
Purpose of the Study:
- To review recent advancements in engineering extracellular vesicles (EVs) for immune regulation.
- To highlight strategies for surface display, cellular targeting, and cargo loading in engineered EVs.
- To explore the application of engineered EVs in cancer immunotherapy and autoimmune diseases.
Main Methods:
- Surface display engineering for antigen specificity and cell targeting.
- Cargo loading strategies for delivering therapeutic molecules (e.g., RNA, cytotoxic agents).
- Development of EVs for specific immune modulation (e.g., immunostimulatory or tolerogenic signals).
Main Results:
- Engineered EVs can integrate multiple functions: antigen specificity, target recognition, and therapeutic delivery.
- Applications include cancer immunotherapy, immune suppression, and antigen-specific tolerance induction.
- Specific examples include antigen-presenting EVs, RNA-loaded EVs, and MSC-derived EVs.
Conclusions:
- Programmable EV immune interfaces represent a versatile foundation for next-generation immunotherapies.
- Engineered EVs can be designed to direct immune responses in a context-dependent manner.
- Clinical translation requires addressing manufacturing, characterization, safety, and regulatory challenges.
Keywords:
EV engineeringMSC-EVcancer immunotherapycargo loadingclinical translationextracellular vesiclesimmune regulationsurface displayMore Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:27Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...